‘Demystify’ Pricing, Say UK Parliamentarians
Executive Summary
UK members of parliament have called on pharmaceutical companies to be more transparent in their pricing process and to improve the way they gather and present data for health technology appraisals. They also say that industry rebates should be ring fenced to fund new medicines.
You may also be interested in...
UK Politicians Want NICE To Use Conditional Reimbursement
A UK parliamentary report has called for the HTA body NICE to consider the use of conditional reimbursement recommendations and more flexible cost-effectiveness thresholds in its ongoing methods review.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.